Please read and agree to the terms and conditions of this site.
@xconomy.com 3 years ago
FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy
@xconomy.com 3 years ago
Two Days, Six IPOs, and $1B Raised for Biotech Research & More
@xconomy.com 3 years ago
FDA Official: New “Playbook” Needed for CMC Reviews of Gene Therapy Products
@xconomy.com 3 years ago
Explore San Diego’s Precision Medicine and Genomics Sector in Xconomy’s New Podcast and Special Report
@xconomy.com 3 years ago
Podcast: How San Diego is Building a Biotech Ecosystem – Genomics & Precision Medicine Experts Weigh in
@xconomy.com 3 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com 4 years ago
Allergan Wins FDA Nod for First Migraine Pill in New Class of Medicines
@xconomy.com 4 years ago
Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More
@xconomy.com 4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com 4 years ago
New PCSK9 Cholesterol Drug Faces Tough Foe. (Hint: Not Cholesterol.)
@xconomy.com 4 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com 4 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com 5 years ago
Bio Roundup: New CRISPR Feud, A NY Splash, Pharma vs. Congress & More
@xconomy.com 5 years ago
Ireland to Sequence 400K Genomes With New Precision Medicine Effort
@xconomy.com 5 years ago
Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues
@xconomy.com 5 years ago
Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More
@xconomy.com 5 years ago
IPO Wave Rolls On as Five Life Science Firms Haul in $651M
@xconomy.com 5 years ago
CRISPR Risks? Researchers Stoke Fears of Cancer in Gene-Edited Cells
@xconomy.com 5 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines
@xconomy.com 5 years ago
Will New Study Cut Guesswork for Depression Medicine Prescriptions?